​

Insight Molecular Diagnostics (IMDX) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

IMDX Stock Forecast

Insight Molecular Diagnostics (IMDX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $8.00, with a high of $8.00 and a low of $8.00. This represents a 20.12% increase from the last price of $6.66.

$2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $8 Low: $8 Last Closed Price: $6.66

IMDX Stock Rating

Insight Molecular Diagnostics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (63.64%), 4 Hold (36.36%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 4 7 Strong Sell Sell Hold Buy Strong Buy

IMDX Price Target Upside V Benchmarks

TypeNameUpside
StockInsight Molecular Diagnostics20.12%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$8.00
Last Closing Price$6.66$6.66$6.66
Upside/Downside--20.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 25112--4
Oct, 25112--4
Sep, 25112--4
Aug, 25112--4
Jul, 25112--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 21, 2025Thomas FlatenUBS$8.00$3.07160.59%20.12%
Apr 24, 2024Mike MatsonNeedham$4.25$2.3878.57%-36.19%
Dec 01, 2022Lake Street$10.00$9.445.93%50.15%
Nov 18, 2022Piper Sandler$10.00$8.5217.37%50.15%
Aug 17, 2022David WestenbergPiper Sandler$30.00$17.4871.62%350.45%
Aug 11, 2022Lake Street$60.00$19.27211.36%800.90%
Aug 11, 2022Needham$42.00$19.02120.82%530.63%
May 15, 2022David WestenbergPiper Sandler$28.00$22.6023.89%320.42%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 21, 2025UBSBuyBuyhold
Oct 15, 2024NeedhamBuyBuyhold
May 16, 2024StephensBuyBuyhold
Apr 24, 2024NeedhamBuyBuyhold
Nov 18, 2022Piper SandlerOverweightNeutraldowngrade
Nov 14, 2022Piper SandlerOverweightOverweighthold
Nov 11, 2022NeedhamBuyBuyhold
Aug 17, 2022Piper SandlerOverweightOverweighthold
Aug 11, 2022Lake StreetBuyBuyhold
Aug 11, 2022NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-4.66---
Avg Forecast$-3.34$-0.99$-0.96$-0.83
High Forecast$-2.50$-0.74$-0.72$-0.62
Low Forecast$-4.43$-1.31$-1.27$-1.10
Surprise %39.52%---

Revenue Forecast

$0 $4M $8M $12M $16M $20M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$1.88M---
Avg Forecast$3.84M$3.04M$4.40M$13.20M
High Forecast$4.80M$3.20M$6.10M$16.49M
Low Forecast$3.10M$2.90M$3.10M$10.64M
Surprise %-51.05%---

Net Income Forecast

$-65M $-53M $-41M $-29M $-17M $-5M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-60.66M---
Avg Forecast$-45.26M$-12.94M$-13.00M$-11.24M
High Forecast$-32.67M$-9.68M$-9.38M$-8.11M
Low Forecast$-57.86M$-17.13M$-16.61M$-14.36M
Surprise %34.02%---

IMDX Forecast FAQ

Is Insight Molecular Diagnostics stock a buy?

Insight Molecular Diagnostics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Insight Molecular Diagnostics is a favorable investment for most analysts.

What is Insight Molecular Diagnostics's price target?

Insight Molecular Diagnostics's price target, set by 11 Wall Street analysts, averages $8 over the next 12 months. The price target range spans from $8 at the low end to $8 at the high end, suggesting a potential 20.12% change from the previous closing price of $6.66.

How does Insight Molecular Diagnostics stock forecast compare to its benchmarks?

Insight Molecular Diagnostics's stock forecast shows a 20.12% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Insight Molecular Diagnostics over the past three months?

  • November 2025: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Insight Molecular Diagnostics’s EPS forecast?

Insight Molecular Diagnostics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.99, marking a -78.76% decrease from the reported $-4.66 in 2024. Estimates for the following years are $-0.96 in 2026, and $-0.83 in 2027.

What is Insight Molecular Diagnostics’s revenue forecast?

Insight Molecular Diagnostics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.04M, reflecting a 61.84% increase from the reported $1.88M in 2024. The forecast for 2026 is $4.4M, and $13.2M for 2027.

What is Insight Molecular Diagnostics’s net income forecast?

Insight Molecular Diagnostics's net income forecast for the fiscal year ending in December 2025 stands at $-12.94M, representing a -78.67% decrease from the reported $-60.663M in 2024. Projections indicate $-12.999M in 2026, and $-11.239M in 2027.